November 29, 2016 - By olga
A well-grounded and judicious transaction was made by the director of Biospecifics Technologies Corp, Mr. Toby Wegman, a few days ago, when he sold amount company shares – 10,000, amounting to $480,832 U.S. Dollars, based on an average weighted cost of $48.1 per each share. Toby filled this sale on 29-11-2016. The 4F filing is freely accessible here at the SEC website. Today, he possess a total of 949,973 shares or 12.65% of Biospecifics Technologies Corp’s market cap.
Insitutional Activity: The institutional sentiment decreased to 1.42 in 2016 Q2. Its down 1.01, from 2.43 in 2016Q1. The ratio dropped, as 7 funds sold all BioSpecifics Technologies Corp. shares owned while 14 reduced positions. 8 funds bought stakes while 43 increased positions. They now own 3.62 million shares or 3.75% more from 3.49 million shares in 2016Q1.
Jpmorgan Chase And last reported 966 shares in the company. Moreover, Bridgeway Management has 0.02% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 24,914 shares. Morgan Stanley accumulated 203 shares or 0% of the stock. Schwab Charles Inv Mgmt Inc accumulated 0% or 44,710 shares. Secor Cap Limited Partnership holds 0.08% or 16,657 shares in its portfolio. Citigroup holds 1,411 shares or 0% of its portfolio. Smith Asset Group Inc Limited Partnership has 0.01% invested in the company for 9,848 shares. The New York-based Mufg Americas Holdings Corporation has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Cornerstone Mngmt Limited Liability Corporation accumulated 3,600 shares or 0% of the stock. Geode Cap Ltd Limited Liability Company holds 0% or 41,498 shares in its portfolio. Moreover, Dimensional Fund L P has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 178,251 shares. New York State Common Retirement Fund accumulated 0% or 10,719 shares. Goldman Sachs reported 36,472 shares or 0% of all its holdings. Jw Asset Mgmt Llc accumulated 2.31% or 72,649 shares. The California-based Clarivest Asset Mgmt Limited Liability Co has invested 0.01% in BioSpecifics Technologies Corp. (NASDAQ:BSTC).
Insider Transactions: Since August 23, 2016, the stock had 0 insider purchases, and 7 insider sales for $1.53 million net activity. Wegman Thomas sold $127,751 worth of stock or 3,100 shares. Wegman Toby sold $135,350 worth of BioSpecifics Technologies Corp. (NASDAQ:BSTC) on Tuesday, September 13.
The stock increased 5.06% or $2.4 on November 29, hitting $49.85. About 82,988 shares traded hands or 162.37% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 33.14% since April 26, 2016 and is uptrending. It has outperformed by 27.88% the S&P500.
BioSpecifics Technologies Corp. is a biopharmaceutical company. The company has a market cap of $338.18 million. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. It has a 32.67 P/E ratio. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development.
According to Zacks Investment Research, “BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals.”
Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on March, 13. They expect $0.38 earnings per share, up 5.56% or $0.02 from last year’s $0.36 per share. BSTC’s profit will be $2.58 million for 32.80 P/E if the $0.38 EPS becomes a reality. After $0.42 actual earnings per share reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.
More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Prnewswire.com which released: “BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results” on November 09, 2016, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of ..” published on November 17, 2016, Quotes.Wsj.com published: “News BioSpecifics Technologies Corp.BSTC” on February 12, 2011. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Prnewswire.com and their article: “BioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results ..” published on November 02, 2016 as well as Seekingalpha.com‘s news article titled: “BioSpecifics Technologies Corp. Has A 6-Year Expiration Date” with publication date: August 03, 2016.
BioSpecifics Technologies Corp. (BioSpecifics), incorporated on November 1, 1990, is a biopharmaceutical company. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. The Company’s injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.